Meridia Fatality Rate “Substantially Lower” Than Obese Population – Abbott
Executive Summary
Abbott's Meridia patient fatality rate is "substantially lower" than what would generally be expected from the obese population, the company maintains in response to a Public Citizen Health Research Group petition calling for the drug's withdrawal
You may also be interested in...
Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing
FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers
Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing
FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers
Meridia labeling
Abbott met with FDA Chief Counsel Daniel Troy July 11 to discuss labeling issues for Meridia (sibutramine). Public Citizen's petition requesting withdrawal of the obesity agent has been pending at FDA since March 2002 (1"The Pink Sheet" March 25, 2002, p. 21)...